Dianthus Therapeutics, Inc. · NASDAQ:DNTH
Dianthus Therapeutics — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
29 slides from Dianthus Therapeutics's conference presentation, Jan 12, 2026
Slide 1: Advancing a leading autoimmune-focused company
Advancing a leading autoimmune-focused company January 12, 2026
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities
Slide 3: Advancing a leading autoimmune-focused company
Advancing a leading autoimmune-focused company Developing two autoimmune therapeutics with best-in-class, pipeline-in-a-product potential and targeting patient-friendly, infrequent S.C. self-administration Claseprubart DNTH212 (aC1s mAb) (BDCA2 and BAFF/APRIL bifunctional fusion protein) • Highly po
Slide 4: Pursuing the power of consistent control…with one-click!
Pursuing the power of consistent control…with one-click! claseprubart CONFIDENCE CLASSICAL CONVENIENCE Aim for Potent, Rapid, Upstream Inhibition of <10-Second Consistent Efficacy Classical Pathway Only Autoinjector Potential for Potential to Preserve One-Click Best-in-Class Profile Immune Function
Slide 5: Claseprubart opportunity as first-line biologic in large and growing US neuromuscular market
Claseprubart has opportunity to compete as a first-line biologic in large and growing US neuromuscular market gMG is just the first step in building a leading neuromuscular franchise with claseprubart >150K patients >10K MMN patients POC supporting classical pathway >140K patients inhibition and lim
Slide 6: Claseprubart: Opportunity to be a Best-in-Class, First-Line Biologic for Generalized Myasthenia Gravis
Claseprubart: Opportunity to be a Best-in- Class, First-Line Biologic for Generalized Myasthenia Gravis
Slide 7: Across key efficacy measures, claseprubart demonstrated robust and clinically meaningful responses
Across key efficacy measures, claseprubart demonstrated robust and clinically meaningful responses Claseprubart Claseprubart 300mg/2mL Q2W 600mg/4mL Q2W Placebo Placebo- Placebo- Absolute Absolute adjusted adjusted MG-ADL mean change from -1.8 -2.6 -2.8 -4.6 -5.4 baseline at Week 13 (P=0.0113)* (P=0
Slide 8: OLE data support addition of 300mg/2mL Q4W in Ph. 3
OLE data support addition of 300mg/2mL Q4W in Ph. 3 PK levels approximately half of 300mg/2mL Q2W steady state resulted in robust reductions on MG-ADL & QMG Mean Change in PBO Patients’ MG-ADL and QMG Score from RCT Baseline to OLE Week 6 Estimated PK QMG MG-ADL QMG: 14.2 of ~65 µg/mL 14.0 PBO Patie
Slide 9: Adding QMG screening criteria in Ph. 3, similar to zilucoplan Ph. 3
Adding QMG screening criteria in Ph. 3, similar to zilucoplan Ph. 31, may better control for placebo response Claseprubart MG-ADL Change from Baseline Zilucoplan Ph. 3 MG-ADL Change from Baseline in Patients All Patients Patients with QMG ≥10 with QMG ≥12 Placebo Claseprubart 300mg Q2W Placebo Clase
Slide 10: Potential for improved efficacy vs. C5 inhibitors due to upstream inhibition
Potential for improved efficacy vs. C5 inhibitors with claseprubart may be due to upstream inhibition Claseprubart Prevents the Creation of Pro-inflammatory Split Products C3a and C3b vs. Ravulizumab C3a Formation1 C3b Deposition2* 10 100 % of hRBC with C3b Deposition 0 80 % Reduction in C3a -20 60
Slide 11: Ph. 3 trial design to include additional Q4W arm and new screening criteria
Ph. 3 trial design to include additional Q4W arm, and new screening criteria of QMG >10 as well as MG-ADL >6 Final Ph. 3 trial design TBD after regulatory consultations Highlights • Design: Male and female subjects S.C. Treatment Period TBD After Consulting with FDA randomized to receive either clas
Slide 12: Achieving this profile could position claseprubart as a potential best-in-disease treatment for gMG
Achieving this profile could position claseprubart as a potential best-in-disease treatment for gMG C5 OR SUPERIOR EFFICACY C1s SAFETY AUTOINJECTOR CONVENIENCE (ULTOMIRIS/SOLIRIS/ZILBRYSQ) (ENJAYMO) (DUPIXENT) Similar or superior MG-ADL to FDA- Comparable safety to FDA-approved Comparable convenienc
Slide 13: Claseprubart: Opportunity to Change the Treatment Paradigm in CIDP
Claseprubart: Opportunity to Change the Treatment Paradigm in Chronic Inflammatory Demyelinating Polyneuropathy
Slide 14: US CIDP market offers substantial growth given high unmet need
The US CIDP market offers substantial growth given the high unmet need and limitations of the current standard of care Opportunity for an active C1s inhibitor with the target profile of claseprubart to replace the standard of care Standard US CIDP Market Opportunity of care1 FcRn Claseprubart ~40,00
Slide 15: Active C1s inhibition has demonstrated clinical POC with potential for equal or superior efficacy
Active C1s inhibition has demonstrated clinical POC with potential for equal or superior efficacy to current SOC IVIG Ph. 2 Riliprubart Data Validates Active C1s in CIDP1 but with High Volume, Weekly Dosing of 600mg/4mL2 Neuromuscular indication with >40,000 high unmet patients in the U.S. and no ap
Slide 16: Claseprubart has superior affinity and potency vs. riliprubart
Claseprubart has superior affinity and potency vs. riliprubart Affinity Assays Functional Assays of Classical Pathway Inhibition Fold DNTH103 riliprubart Improvement Binding CH50 assay of RBC lysis Affinity KinExa 9pM 75pM ~8X in human serum3 Wieslab classical pathway Liposome lysis to human active
Slide 17: CIDP Ph. 3 pivotal trial includes open-label Part A testing target dose
CIDP Ph. 3 pivotal trial includes open-label Part A testing the target dose of 300mg/2mL S.C. Q2W CIDP interim responder analysis with first 40 patients in Part A anticipated in Q2’26 PART B: 52-Week Pbo- Highlights controlled RCT • Design: All subjects receive claseprubart in Responders Randomized
Slide 18: Key differences between ADHERE and CAPTIVATE trials make cross-trial comparisons challenging
Key differences between ADHERE and CAPTIVATE trials make cross-trial comparisons challenging Efgartigimod (FcRn) Claseprubart (aC1s) Considerations Key Differentiators of CAPTIVATE S.C. QW 300mg/2mL S.C. Q2W Enrolling a broad population of Ph. 3 Study CIDP patients, including SOC- Populations SoC-Tr
Slide 19: Claseprubart: Opportunity to be Best-in-Class in Multifocal Motor Neuropathy
Claseprubart: Opportunity to be Best-in-Class in Multifocal Motor Neuropathy
Slide 20: US MMN market is underdiagnosed with need for more effective and convenient treatment
The US MMN market is underdiagnosed with a need for more effective and convenient treatment options Opportunity for the target profile of claseprubart to become the new standard of care in MMN Standard Claseprubart of care2 target profile US MMN Market Opportunity ~10,000 pts Opportunity (~11% CAGR)
Slide 21: MMN is an attractive opportunity with clinical PoC via classical pathway inhibition
MMN is an attractive opportunity with clinical PoC demonstrated via classical pathway inhibition Empasiprubart (Q1-2W I.V., C2 inhibitor) Ph. 2 Data Demonstrating Efficacy Signals1 EMPA I.V. Placebo Neuromuscular indication with high unmet >10,000 No approved targeted patients in the U.S. biologic t
Slide 22: Claseprubart demonstrates superior classical pathway potency vs. empasiprubart
Claseprubart demonstrates superior classical pathway potency vs. empasiprubart Empasiprubart Published Classical Pathway Potency Data Using Claseprubart Demonstrates Superior Classical Pathway the Quidel MicroVue CH501 Potency Head-to-head vs. Empasiprubart Using Same Assay ~6X more potent at IC50 “
Slide 23: Claseprubart has potential to dominate the MMN market with best-in-class target profile
Claseprubart has the potential to dominate the MMN market with its best-in-class target product profile Considerations Empasiprubart (C2)* Claseprubart (active C1s)* Key Differentiators of Claseprubart Claseprubart has ~6x more potent than empasiprubart MMN is an IgM and Published classical pathway3
Slide 24: MMN Phase 2 top-line data anticipated 2H'26
MMN Phase 2 top-line data anticipated 2H’26 A global, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and PK / PD of claseprubart administered S.C. following initial loading dose Highlights 17-Week S.C. Treatment • Design: 36 participants randomized
Slide 25: DNTH212: Potential Best-in-Class Bispecific Fusion Protein for Multiple Autoimmune Indications
DNTH212: Potential Best-in-Class Bispecific Fusion Protein for Multiple Autoimmune Indications
Slide 26: DNTH212 is a bifunctional BDCA2 and BAFF/APRIL inhibitor targeting two validated pathways
DNTH212 is a bifunctional BDCA2 and BAFF/APRIL inhibitor targeting two validated pathways Anti-BDCA2 Antibody Potent inhibition of Type 1 interferon • Inhibiting BDCA2 reduces Type 1 interferon TACI-CRD2 Domain production from plasmacytoid dendritic Potent reduction of Ig levels via cells (pDCs) BAF
Slide 27: DNTH212 TPP aims to deliver superior efficacy in a safe, well-tolerated therapy
DNTH212 TPP aims to deliver superior efficacy in a safe and well-tolerated therapy with patient friendly convenience EFFICACY SAFETY CONVENIENCE Bifunctional approach has Inhibiting Type 1 interferon or Targeting patient friendly S.C. potential for superior efficacy in BAFF/APRIL has been self-admin
Slide 28: Advancing a leading autoimmune-focused biotech with two clinical stage programs
Advancing a leading autoimmune-focused biotech with two- clinical stage programs Program Indication Ph. 1 Ph. 2 Ph. 3 Upcoming Milestones gMG • Expect to initiate Ph. 3 study in 2026 >100,000 U.S. Patients • Interim responder analysis expected in Q2’26 Claseprubart CIDP aC1s >40,000 U.S. Patients •
Slide 29: Advancing a leading autoimmune-focused company
Advancing a leading autoimmune-focused company January 12, 2026
Dianthus Therapeutics — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix